Madrigal Pharmaceuticals, Inc. (MDGL) Business Profile

What it does

Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. The disease involves fat buildup, inflammation and damage in the liver and can progress to cirrhosis, liver failure or liver cancer. Bill Sibold is its chief executive officer.

Madrigal’s first and only approved medicine is Rezdiffra, also called resmetirom. It is a once-daily oral treatment directed at the liver. In the United States, it is approved alongside diet and exercise for adults with noncirrhotic MASH and moderate to advanced liver scarring, known as F2 to F3 fibrosis. It also has conditional marketing authorization in Europe for that patient group.

The company sells Rezdiffra in the United States and Germany. It works with healthcare providers and payers to support prescribing and access. Its research also addresses patients with compensated MASH cirrhosis, a more advanced stage in which the liver is scarred but generally retains normal function. Rezdiffra is not yet approved for that use.

Beyond Rezdiffra, Madrigal has licensed drug candidates intended to treat MASH through other biological mechanisms. These include MGL-2086, an oral GLP-1 drug; ervogastat, which targets fat production in the liver; and gene-silencing programs. The company is exploring whether such treatments could be used alongside resmetirom.

How it makes money

Madrigal generates product revenue from sales of Rezdiffra. Treatment is taken daily, and the company reports the number of patients actively on therapy at quarter-end after discontinuations. Prescribers decide whether to use the medicine, while insurance coverage and patients’ out-of-pocket costs affect access.

Net product revenue was $958.4 million in 2025; net sales were $431.3 million in the third quarter of 2026.

Reported revenue is net of deductions including discounts, returns, chargebacks, rebates and co-payment assistance. For example, chargebacks arise when a customer buys the medicine from Madrigal and supplies an eligible healthcare provider at a lower contracted price. Rebates include amounts paid to government programs and commercial payers. Madrigal estimates these deductions and reviews them each reporting period.

Madrigal has secured broad first-line access across commercial payers. It said it was negotiating Medicare Part D contracts expected to take effect in Q1 2027. The company’s commercial activities include educating physicians and patients, supporting care pathways and engaging payers.

Madrigal pays Roche tiered single-digit royalties on net sales of Rezdiffra under the agreement through which it holds exclusive worldwide rights to resmetirom. The company also spends on trials, licenses and commercialization. It reported net income of $55.4 million in the third quarter of 2026, its first profitable quarter, but said it could move in and out of profitability as investments and business-development spending vary.

Customers and how it sells

Rezdiffra is prescribed for adults with eligible MASH, with physicians, patients and third-party payers all affecting whether treatment is used. Madrigal initially focused its U.S. commercial efforts on liver and digestive-disease specialists. It later expanded its field team to target selected endocrinologists who care for MASH patients.

The company’s U.S. launch began in April 2024, and its German launch followed in September 2025. Madrigal expects further European launches to proceed country by country, depending on reimbursement procedures and regulatory approval where required. It may use third-party distributors in smaller European countries and other international markets.

Customer A accounted for 34.0% of revenue in FY2025. Customer B accounted for 22.0% of revenue in FY2025. Customer C accounted for 15.0% of revenue in FY2025. Customer D accounted for 12.0% of revenue in FY2025. These figures describe customers purchasing from the company, not the share of patients treated by individual physicians.

Madrigal estimated that the diagnosed U.S. F2–F3 MASH market had expanded to more than 530,000 patients as of June 30, 2026. It also estimated that Rezdiffra had penetrated approximately 10% of the diagnosed market.

Suppliers and costs

Madrigal relies on third-party manufacturers for commercial Rezdiffra supplies and must monitor those arrangements for compliance with its standards and regulatory requirements. It also contracts with clinical research organizations to manage trials and uses outside trial sites, laboratories, consultants and manufacturers in development.

Cost of sales includes manufacturing and distribution costs and royalties payable to Roche. Madrigal expects this cost to rise because manufacturing costs incurred before regulatory approval were expensed as research and development rather than capitalized as inventory. The company also incurs costs for commercial staff and marketing, clinical studies, intellectual property and licensed programs.

For 2025, research and development expenses were $388.5 million, including upfront expenses under the CSPC and Pfizer license agreements. Selling, general and administrative expenses were $813.8 million, reflecting increased commercial activity and headcount. Madrigal had approximately $268.3 million of obligations as of December 31, 2025 under agreements related to active pharmaceutical ingredient, expected to be paid through 2029.

In the third quarter of 2026, cost of sales was $37.8 million, primarily driven by increased royalties payable to Roche. Madrigal expects to continue spending on product development and commercialization.

Competitive position

Rezdiffra was the first medicine approved in both the United States and Europe for noncirrhotic MASH with moderate to advanced fibrosis. Novo Nordisk’s semaglutide has since received FDA approval for MASH and was pending approval in the EU. Madrigal said competition with Novo’s Wegovy had not affected its growth.

Other companies conducting Phase 3 MASH trials include Inventiva, Roche, Eli Lilly and Boehringer Ingelheim. Roche is also Madrigal’s licensor for resmetirom. Competition can turn on efficacy, safety, drug interactions, administration, pricing, reimbursement and promotion. Madrigal faces potential competition from drugs already marketed for other uses as well as therapies in development.

A U.S. patent covering Rezdiffra’s approved weight-threshold dosing regimen provides protection to February 2045. Madrigal has also built a prescriber base and obtained broad first-line commercial payer access. It estimates that Rezdiffra has reached approximately 10% of the diagnosed MASH market.

Our reading: The dosing patent and established commercial access offer protection, but the patent covers a specific regimen rather than every possible MASH treatment. Our reading: Rezdiffra’s early launch and prescriber relationships provide a foothold, although an approved rival and other late-stage programs can compete on treatment characteristics and access.

Growth opportunities

Madrigal’s growth plans include adding Rezdiffra patients within its current indication, expanding into more European countries and seeking approval for more advanced disease. The company estimates that the diagnosed U.S. F2–F3 market exceeded 530,000 patients at June 30, 2026, and expects the market to grow more than 30% by the end of 2026. It attributes market growth primarily to increased awareness and diagnosis.

Madrigal estimates that 360,000 U.S. patients with compensated MASH cirrhosis are addressable, up from its prior estimate of 245,000. Its event-driven MAESTRO-NASH OUTCOMES trial is testing Rezdiffra in that population. The company expects data in late 2027 and says positive results could support both an F4c indication and full U.S. approval for the existing F2–F3 indication.

The company is also planning a Phase 3 MAESTRO-CSPH trial focused on patients with clinically significant portal hypertension. It plans to finalize the protocol after discussions with the FDA and initiate the trial in the first half of 2027.

Its licensed pipeline offers additional development paths. Madrigal is evaluating an oral GLP-1 candidate and an oral DGAT2 inhibitor for potential combinations with resmetirom, as well as gene-silencing approaches. These candidates require clinical development and, before commercialization, regulatory approval.

Structural risks

• Dependence on one medicine. Madrigal’s prospects depend on Rezdiffra, its only approved product. Its U.S. approval is accelerated and its European authorization is conditional; the company has post-marketing commitments to demonstrate clinical benefit.

• Trial and approval uncertainty. The outcomes trial is event-driven, and its timing depends on the required events accruing. A positive result is needed to support the intended expansion into compensated cirrhosis and full approval. Other pipeline candidates also face clinical and regulatory uncertainty.

• Market access and competition. Physician and patient acceptance, insurance coverage, reimbursement and out-of-pocket costs affect use. Rezdiffra also competes with approved treatments and may face additional products in development.

• Manufacturing and supply. Madrigal must maintain and monitor third-party manufacturing arrangements, meet regulatory standards and supply Rezdiffra at acceptable costs. Regulatory action could restrict manufacturing or marketing, or lead to a withdrawal.

• Spending and financing. Commercial expansion, trials and business development require spending. Madrigal expects additional operating losses and says it may need more capital for long-term requirements; financing may not be available on acceptable terms, or at all.

Bottom line

Our reading

Madrigal is a single-product commercial drug company using Rezdiffra sales to support expansion and a broader MASH pipeline (item1; item7). Its early launch, patent and payer access provide a commercial foothold, but continued approval, competition and outcomes-trial results remain central exposures (item1; item1a; call_qa). Recent quarterly profitability adds financial capacity, although spending and business-development timing can make profitability uneven (call_prepared).